In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery

Human Gene Therapy

Volumn 10, Issue 1, 1999, Pages 77-84

  Iqbal Ahmed, C M ^a   Sugarman, Barry J ^a   Johnson, Duane E ^a   Bookstein, Robert E ^a   Saha, Deba P ^a   Nagabhushan, T L ^a   Wills, Ken N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; LIVER CELL CARCINOMA; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CYTOMEGALOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOASSAY; INTERFERON ALFA-2B; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 2442765398     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950019200     Document Type: Article

References (22)

1. ADOLF, G.R., KALSNER, I., AHORN, H., MAURER-FOGY, I., and CANTELL, K. (1991). Natural human interferon-α2 is O-glycosylated. Biochem. J. 276, 511-518.
2. ANDERSON, K.P., and FENNIE, E.H. (1987). Adenovirus early region 1A modulation of Interferon antiviral activity. J. Virol. 61, 787-795.
3. BORDENS, R., GROSSBERG, S.E., TROTTA, P.P., and NAGABHUSHAN, T.L. (1997). Molecular and biologic characterization of interferon-α2b. Semin. Oncol. 24, S9, 41-51.
4. GRAHAM, F.L., and PREVEC, L. (1991). Manipulation of adenovirus vectors. Methods Mol. Biol. 7, 109-128.
5. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from adenovirus type 5. J. Gen. Virol. 36, 59-74.
6. GUTCH, M.J., and REICH, N.C. (1991). Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc. Natl. Acad. Sci. U.S.A. 88, 7913-7917.
7. GUTTERMAN, J.U. (1994). Cytokine therapeutics: Lessons from interferon α. Proc. Natl. Acad. Sci. U.S.A. 91, 1198-1205.
8. HUYGHE, B.G., LIU, X., SUTJIPTO, S., SUGARMAN, B.J., HORN, M.T., SHEPARD, H.M., SCANDELLA, C.J., and SHABRAM, P. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403-1416.
9. KALVAKOLANU, D.V.R., BANDYOPADHYAY, S.K., HARTER, M.L., and SEN, G.C. (1991). Inhibition of interferon-inducible gene expression by adenovirus E1A protein: Block in transcriptional complex formation. Proc. Natl. Acad. Sci. U.S.A. 88, 7459-7463.
10. KOZARSKY, K.F., and WILSON, J.M. (1993). Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3, 499-503.
11. LABDON, J.E., GIBSON, K.D., SUN, S., and PESTKA, S. (1984). Some species of human leukocyte interferon are glycosylated. Arch. Biochem. Biophys. 232, 422-426.
12. LENGYEL, P. (1993). Tumor-suppressor genes: News about the interferon connection. Proc. Natl. Acad. Sci. U.S.A. 90, 5893-5895.
13. NAGABHUSHAN, T.L., and TROTTA, P.P. (1989). Interferons. In Ullman's Encyclopedia of Industrial Chemistry. (VCH Publishers, Weinheim, Germany) p. A14.
14. NAGABHUSHAN, T.L., and GIAQUINTO, A. (1994). Regulatory Practice for Biopharmaceutical Production. A.S. Lubiniecki and S.A. Vargo, eds. (Wiley-Liss, New York).
15. OBENAUER-KUTNER, L.J., JACOBS, S.J., KOLZ, K., TOBIAS, L.M., and BORDENS, R.W. (1997). A highly sensitive electrochemiluminescence immunoassay for interferon α2b in human serum. J. Immunol. Methods 206, 25-33.
16. PFEFFER, L.M. (1997). Biologic activities of natural and synthetic type interferons. Semin. Oncol. 24(Suppl. 9), 63-69.
17. RAZIUDDIN, A., SARKAR, F.H., DUTKOWSKI, R., SHULMAN, L., RUDDLE, F.H., and GUPTA, S.L. (1984). Receptors for human alpha and beta interferon but not gamma interferon are specified by human chromosome 21. Proc. Natl. Acad. Sci. U.S.A. 81, 5504-5508.
18. SMITH, R.C., WILLS, K.N., ANTELMAN, D., PERLMAN, H., TRUONG, L.N., KARSINSKI, K., and WALSH, K. (1997). Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 96, 1899-1905.
19. TUTING, T., GAMBOTTO, A., BAAR, J., DAVIS, I.D., STORKUS, W.J., ZAVODNY, P.J., NARULA, S., TAHARA, H., ROBBINS, P.D., and LOTZE, M.T. (1997). Interferon a gene therapy for cancer: Retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther. 4, 1053-1060.
20. WILLS, K.N., MANEVAL, D.C., MENZEL, P., HARRIS, M.P., SUTJIPTO, S., VAILLANCOURT, M.T., HUANG, W.M., JOHNSON, D.E., ANDERSON, S.C., WEN, S.F., BOOKSTEIN, R., SHEPARD, H.M., and GREGORY, R.J. (1994). Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5, 1079-1088.
21. WILLS, K.N., HUANG, W.-M., HARRIS, M.P., MACHEMAR, T., MANEVAL, D.C., and GREGORY, R.J. (1995). Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 3, 191-197.
22. ZHANG, J., HU, C., GENG, Y., SELM, J., KLEIN, S.B., ORAZI, A., and TAYLOR, M.W. (1996). Treatment of a human breast xenograft with adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 4513-4518.